Business
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued
About this update from Jupiter Neurosciences, Inc.
[{"type":"image","alt":"Jupiter Neurosciences, Inc.","displaySize":"","headline":null,"caption":"Jupiter Neurosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pYMq4mt4Y617fyJqYqyXSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6","width":300,"height":89}},"lazy":false},{"type":"text","content":"Repayment Commencement Deferred to April 1, 2026","length":48,"tagName":"p"},{"type":"text","content":"Core Economic Terms of $6.0 Million Financing Remain Unchanged","length":62,"tagName":"p"},{"type":"text","content":"JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company’s Standby Equity Purchase Agreement.","length":443,"tagName":"p"},{"type":"text","content":"Under the amendment:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Monthly installment payments will now begin on April 1, 2026","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Principal repayments will follow a defined schedule agreed between the Company and Yorkville","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":152,"olType":false},{"type":"text","content":"The amendment does not introduce any new pricing provisions, reset features or additional financing commitments. The amendment relates solely to installment timing and application mechanics and does not alter the underlying economic terms of the financing.","length":256,"tagName":"p"},{"type":"text","content":"“This amendment reflects a deliberate and aligned decision between Jupiter and Yorkville,” said Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences. “Yorkville demonstrated its commitment to our long-term strategy by adjusting installment timing without changing pricing, maturity or other economic terms. That alignment en...